Porównaj metody

	Ocena wieloośrodkowa testu przesiewowego	Ocena testów przesiewowych
Dziedzina	Epidemiologia	Epidemiologia
Rodzina	Process / pipeline	Process / pipeline
Rok powstania	1976–2003 (core diagnostic accuracy framework; multicenter STARD standards formalized 2003)	1968 (Wilson-Jungner principles); statistical framework developed 1970s–2000s
Twórca	Methodological consensus (STARD group, Bossuyt et al.); broader diagnostic accuracy tradition rooted in Hanley & McNeil (1982) and Sackett & Haynes (1976)	Wilson & Jungner (WHO criteria, 1968); foundational work by Pepe, Altman, and others in statistical test evaluation
Typ	Observational diagnostic accuracy study	Observational diagnostic / epidemiological evaluation design
Źródło pierwotne	Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003). Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Annals of Internal Medicine, 138(1), 40-44.	Wilson, J. M. G., & Jungner, G. (1968). Principles and Practice of Screening for Disease. World Health Organization. Public Health Papers No. 34.
Inne nazwy	multicenter diagnostic accuracy study, multisite screening evaluation, multicenter test performance study, multicenter DTA study	screening study, screening performance evaluation, screening accuracy assessment, STE
Pokrewne	6	6
Podsumowanie	A multicenter screening test evaluation measures the diagnostic accuracy of a screening test — its sensitivity, specificity, predictive values, and ROC-curve area — by enrolling participants across two or more independent clinical sites. Conducting the study at multiple centers broadens the patient spectrum, tests generalizability across different laboratory conditions and patient populations, and produces more externally valid accuracy estimates than a single-center study.	Screening test evaluation is a systematic epidemiological approach for assessing whether a test or program can accurately and cost-effectively identify individuals with a condition before symptoms appear. It quantifies diagnostic performance metrics — sensitivity, specificity, predictive values, and the ROC curve — and evaluates whether a screening program meets established public health criteria for adoption and harm-benefit balance.